接受乌帕替尼治疗的类风湿关节炎患者对佐剂重组带状疱疹疫苗的免疫原性:随机对照试验子研究的60周结果
SELECT-COMPARE试验子研究纳入93例接受乌帕替尼15 mg每日一次联合甲氨蝶呤的类风湿关节炎患者,于第0周和第12周接种佐剂重组带状疱疹疫苗(RZV)。第16周87.8%(95%CI 81.0-94.5)患者达到满意体液免疫应答,各时间点均超过60%患者达到细胞免疫应答,未报告严重不良事件。
要点
- 第16周87.8%患者达到满意体液免疫应答(抗gE抗体较接种前≥4倍升高)。
- 各时间点均超过60%患者达到细胞免疫应答(gE特异性CD4+[2+]T细胞频率较接种前≥2倍升高)。
- 年龄和合并使用糖皮质激素未影响RZV抗体应答,未报告严重不良事件。
核心结论
- 大多数接受乌帕替尼15 mg每日一次联合甲氨蝶呤的患者在第二剂RZV接种后4周(第16周)达到满意的体液免疫和细胞免疫应答。
研究设计与样本
- SELECT-COMPARE(NCT02629159)随机对照试验子研究,纳入接受乌帕替尼15 mg每日一次联合甲氨蝶呤的类风湿关节炎患者,于第0周和第12周接种RZV。
- 共93例患者接受两剂RZV,78.5%为女性,平均年龄62.4岁;基线时49.5%使用合并糖皮质激素(中位日剂量5.0 mg)。
- 在第0、4、16和60周采集抗体滴度;在38例患者的亚队列中评估细胞免疫应答;每次接种后30天内评估安全性。
主要发现
- 第16周87.8%(95%CI 81.0-94.5)患者达到满意体液免疫应答(抗gE抗体滴度较接种前≥4倍升高)。
- 年龄和合并使用糖皮质激素未影响RZV抗体应答。
- 各时间点均超过60%患者达到细胞免疫应答(gE特异性CD4+[2+]T细胞频率较接种前≥2倍升高)。
- 未报告严重不良事件;1例患者在第二剂RZV接种后4个月发生带状疱疹。
关键数值与推荐
- 主要终点为第16周达到满意体液免疫应答的患者比例,定义为抗gE抗体滴度较接种前≥4倍升高。
- 细胞免疫应答定义为gE特异性CD4+[2+]T细胞频率较接种前≥2倍升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the immunogenicity of adjuvanted recombinant zoster vaccine (RZV) in patients with rheumatoid arthritis receiving upadacitinib 15 mg once daily (QD) with background methotrexate. METHODS: Eligible patients in SELECT-COMPARE (NCT02629159) receiving upadacitinib 15 mg QD and background methotrexate received RZV at weeks 0 and 12. Antibody titres were collected at weeks 0, 4, 16 and 60 (prevaccination, 4 weeks after first dose, and 4 and 48 weeks after second dose). The primary endpoint was the proportion of patients achieving a satisfactory humoral response to RZV at week 16 (≥ 4-fold increase in prevaccination anti-glycoprotein E (gE) antibody titres). Cell-mediated immune (CMI) response to RZV (≥ 2-fold increase in prevaccination gE-specific CD4+ [2+] T-cell frequency) was assessed at each time point in a subcohort of 38 patients. Safety was assessed for 30 days after each vaccination. RESULTS: Overall, 93 patients received both RZV doses (78.5% female; mean age, 62.4 years). At baseline, 49.5% used concomitant corticosteroids (median daily dose, 5.0 mg). Satisfactory humoral responses to RZV were observed in 87.8% (95% CI 81.0 to 94.5) of patients at week 16. Age and concomitant corticosteroid use did not affect RZV antibody response. Over 60% of patients achieved a CMI response to RZV at all time points. No serious adverse events were reported. One patient developed herpes zoster 4 months after the second RZV dose. CONCLUSIONS: Most patients receiving upadacitinib 15 mg QD with background methotrexate achieved satisfactory humoral and CMI responses 4 weeks after the second RZV vaccination (week 16).
引用
- Winthrop KL, Klaff J, Penn SK, et al. Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy. RMD Open. 2025. PMID: 40803820. doi:10.1136/rmdopen-2025-005521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。